drugset / Trial / NCT04794699
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).
Timeline
- Start
- 2021-04-14
- Primary completion
- 2027-01-07
- Completion
- 2027-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IDE397 | Small molecule | — | Oral |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | — | Intravenous |